Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.

Wu LT, Schlenger WE, Galvin DM.

Drug Alcohol Depend. 2006 Sep 1;84(1):102-13. Epub 2006 Feb 17. Erratum in: Drug Alcohol Depend. 2007 Jan 12;86(2-3):301.

2.

Club drug use among youths in treatment for substance abuse.

Hopfer C, Mendelson B, Van Leeuwen JM, Kelly S, Hooks S.

Am J Addict. 2006 Jan-Feb;15(1):94-9.

PMID:
16449098
3.

[Club drugs].

Guerreiro DF, Carmo AL, da Silva JA, Navarro R, Góis C.

Acta Med Port. 2011 Sep-Oct;24(5):739-56. Epub 2011 Dec 29. Review. Portuguese.

4.

Typology of club drug use among young adults recruited using time-space sampling.

Ramo DE, Grov C, Delucchi K, Kelly BC, Parsons JT.

Drug Alcohol Depend. 2010 Mar 1;107(2-3):119-27. doi: 10.1016/j.drugalcdep.2009.09.014. Epub 2009 Nov 24.

5.

Club drugs: reasons for and consequences of use.

Parks KA, Kennedy CL.

J Psychoactive Drugs. 2004 Sep;36(3):295-302.

PMID:
15559677
6.

Use of and attitudes toward club drugs by medical students.

Horowitz A, Galanter M, Dermatis H, Franklin J.

J Addict Dis. 2008;27(4):35-42. doi: 10.1080/10550880802324705.

PMID:
19042589
7.

Club drug use and dependence among young adults recruited through time-space sampling.

Parsons JT, Grov C, Kelly BC.

Public Health Rep. 2009 Mar-Apr;124(2):246-54.

8.

Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.

Smith KM, Larive LL, Romanelli F.

Am J Health Syst Pharm. 2002 Jun 1;59(11):1067-76. Review.

PMID:
12063892
9.

Differences in club drug use between heterosexual and lesbian/bisexual females.

Parsons JT, Kelly BC, Wells BE.

Addict Behav. 2006 Dec;31(12):2344-9. Epub 2006 Apr 24.

10.

Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine.

Gahlinger PM.

Am Fam Physician. 2004 Jun 1;69(11):2619-26. Review.

11.

Club drugs: coming to a patient near you.

Talbert JJ.

Nurse Pract. 2014 Mar 13;39(3):20-5; quiz 25-6. doi: 10.1097/01.NPR.0000443227.72357.72.

PMID:
24481485
12.

Rave drugs: pharmacological considerations.

Klein M, Kramer F.

AANA J. 2004 Feb;72(1):61-7. Review.

PMID:
15098519
13.

The effects and consequences of selected club drugs.

Freese TE, Miotto K, Reback CJ.

J Subst Abuse Treat. 2002 Sep;23(2):151-6. Review.

PMID:
12220613
14.

Recent trends in the use of "club drugs": an Australian review.

Degenhardt L, Copeland J, Dillon P.

Subst Use Misuse. 2005;40(9-10):1241-56. Review.

PMID:
16048815
15.

A brief overview of the clinical pharmacology of "club drugs".

Britt GC, McCance-Katz EF.

Subst Use Misuse. 2005;40(9-10):1189-201. Review.

PMID:
16048813
16.

Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.

Uosukainen H, Tacke U, Winstock AR.

Int J Drug Policy. 2015 Jan;26(1):78-83. doi: 10.1016/j.drugpo.2014.07.004. Epub 2014 Jul 15.

PMID:
25107829
17.

Profiles of club drug users in treatment.

Maxwell JC, Spence RT.

Subst Use Misuse. 2005;40(9-10):1409-26.

PMID:
16048825
18.

A contextual profile of club drug use among adults in Chicago.

Fendrich M, Wislar JS, Johnson TP, Hubbell A.

Addiction. 2003 Dec;98(12):1693-703.

PMID:
14651501
19.

The epidemiology of GHB and ketamine use in an Australian household survey.

Degenhardt L, Dunn M.

Int J Drug Policy. 2008 Aug;19(4):311-6. Epub 2007 Oct 24.

PMID:
17920826
20.

Acute toxic effects of club drugs.

Gable RS.

J Psychoactive Drugs. 2004 Sep;36(3):303-13. Review.

PMID:
15559678

Supplemental Content

Support Center